Findings

What do systematic reviews say?

873 questions · 883 findings · 38 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 319 · 36.1%GRADE not reported 18 · 2%Very low 198 · 22.4%Low 186 · 21.1%Moderate 147 · 16.6%High 15 · 1.7%

Summary of findings: liprotamase vs porcine PERT

Adverse events · children aged 7 years or over and adults with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 128 participants
Low

Summary of findings: liprotamase vs porcine PERT

Pulmonary exacerbations · children aged 7 years or over and adults with cystic fibrosis

Summary of findings: liprotamase showed no clear difference in pulmonary exacerbations: number of exacerbations compared with porcine PERT (low certainty).

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
OR 0.56 [0.13, 2.45]
1 study · 128 participants
Low

Summary of findings ‐ Exercise A vs Exercise B

Balance ( · participants with haemophilia

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Summary of findings ‐ Exercise A vs Exercise B

Reduction in pain intensity · participants with haemophilia

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Low

Summary of findings ‐ Exercise A vs Exercise B

Functional capacityAssessed: 6MWT · participants with haemophilia

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Summary of findings ‐ Exercise A vs Exercise B

Range of Motion: flexion and extension · participants with haemophilia

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Low

Summary of findings ‐ Exercise A vs Exercise B

Strength: flexors and extensors · participants with haemophilia

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 90 participants
Moderate

Summary of findings ‐ Exercise A vs Exercise B

Adverse events · participants with haemophilia

The review found no eligible studies for this question.

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Exercise A vs Exercise B

Quality of life · participants with haemophilia

The review found no eligible studies for this question.

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs placebo

Pain alterationa · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 784 participants
Moderate

Hydroxyurea vs observation

Pain alteration · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs observation

Life‐threatening illness · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Death during the study · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Measures of HbF · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Measures of ANC · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs placebo

Life‐threatening illness · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 759 participants
Moderate

Hydroxyurea vs observation

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs observation

Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs no hydroxyurea

Pain alteration · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs no hydroxyurea

Life‐threatening illness · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found